Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06GHM
|
|||
| Former ID |
DNC009255
|
|||
| Drug Name |
2,7-Bis[3-(butylamino)propionamido]anthraquinone
|
|||
| Synonyms |
2,7-Bis[3-(butylamino)propionamido]anthraquinone; SCHEMBL4289808; CHEMBL479984
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H36N4O4
|
|||
| Canonical SMILES |
CCCCNCCC(=O)NC1=CC2=C(C=C1)C(=O)C3=C(C2=O)C=C(C=C3)NC(=O)CCNCCCC
|
|||
| InChI |
1S/C28H36N4O4/c1-3-5-13-29-15-11-25(33)31-19-7-9-21-23(17-19)28(36)24-18-20(8-10-22(24)27(21)35)32-26(34)12-16-30-14-6-4-2/h7-10,17-18,29-30H,3-6,11-16H2,1-2H3,(H,31,33)(H,32,34)
|
|||
| InChIKey |
WKRXVGOZDDYFGG-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TERT messenger RNA (TERT mRNA) | Target Info | Inhibitor | [1] |
| KEGG Pathway | HTLV-I infection | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
| Regulation of Telomerase | ||||
| IL2 signaling events mediated by PI3K | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Formation of the beta-catenin:TCF transactivating complex | |||
| WikiPathways | TGF beta Signaling Pathway | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Telomere Maintenance | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.